HC Wainwright Decreases Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for Gossamer Bio in a research note issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.24 for the year, down from their prior estimate of $0.28. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.55 EPS.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $7.02 million.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Gossamer Bio has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Trading Down 0.7 %

Shares of Gossamer Bio stock opened at $1.35 on Wednesday. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a market cap of $306.75 million, a PE ratio of -4.22 and a beta of 1.86. The company has a 50-day moving average of $1.16 and a two-hundred day moving average of $0.98.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GOSS. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio during the 4th quarter worth approximately $32,000. US Bancorp DE purchased a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $39,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio during the 4th quarter worth approximately $43,000. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $67,000. Finally, Velan Capital Investment Management LP purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $68,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.